Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML18 Trial for Older Patients with Acute Myeloid Leukaemia and High-risk Myelodysplastic Syndrome
2013-002730-21Phase 2Unknown
- Sponsor
- Cardiff University
- Start
- Oct 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of quizartinib, gemtuzumab ozogamicin, cladribine, vosaroxin, decitabine and 1 more in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Cardiff University. Status: unknown.
02
Drugs
quizartinibgemtuzumab ozogamicincladribinevosaroxindecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2013-002730-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002730-21.